As stated above, the recurrent Y641 EZH2 mutation in DLBCL and FL prevents JAK2-mediated phosphorylation and BTRC-mediated proteasomal degradation, leading to stabilization of EZH2 expression [41]. The gene discussed is EZH2; the disease is diffuse large B-cell lymphoma.